氢气吸入对宫颈癌同步放化疗患者急性放射性肠炎及炎症反应的临床疗效
3 L/min,2 h/d)。结果显示氢气组C反应蛋白、中性粒细胞与淋巴细胞比值、白细胞介素6及粪便隐血阳性率显著降低(P < .05),临床评分和肠炎分级更轻,且肿瘤疗效无显著差异,未见氢气吸入相关不良事件。
要点
- 氢气吸入可显著降低宫颈癌同步放化疗患者炎症标志物水平及粪便隐血阳性率(P < .05)。
- 氢气组LENT-SOMA和PG-SGA评分更低、RTOG肠炎分级更轻(P < .05)。
- 氢气吸入不影响同步放化疗抗肿瘤疗效,且未报告相关不良事件。
核心结论
- 氢气吸入是安全有效的辅助治疗,可显著减轻宫颈癌同步放化疗患者的炎症反应和急性放射性肠炎临床症状,且不损害抗肿瘤疗效。
研究设计与样本
- 前瞻性随机对照研究,纳入接受同步放化疗的宫颈癌患者,实验组28例、对照组30例。
- 实验组在每个放疗日接受氢氧混合气(66.6%氢气、33.3%氧气;3 L/min,2 h/d)吸入治疗。
主要发现
- 氢气组C反应蛋白、中性粒细胞与淋巴细胞比值、白细胞介素6及粪便隐血阳性率显著低于对照组(P < .05)。
- 氢气组LENT-SOMA评分、PG-SGA评分更低,RTOG肠炎分级更轻(P < .05)。
- 两组基于RECIST的肿瘤疗效无显著差异,未报告氢气吸入相关不良事件。
- 两组基线特征(年龄、肿瘤分期、病理及手术史)均衡(P > .05)。
关键数值与推荐
- 氢气吸入方案:氢氧混合气含66.6%氢气、33.3%氧气,流量3 L/min,每日2 h,在每个放疗日进行。
- 炎症标志物包括C反应蛋白、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及白细胞介素6。
- 临床评估工具包括LENT-SOMA评分、PG-SGA评分、RTOG肠炎分级及RECIST疗效评价。
临床怎么用
- 对于接受同步放化疗的宫颈癌患者,可考虑在放疗日辅以氢氧混合气吸入以减轻急性放射性肠炎和全身炎症反应。
- 氢气吸入未显示干扰抗肿瘤疗效,可作为支持治疗手段整合入放疗流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Acute radiation enteritis (ARE) is a common toxic inflammatory reaction in patients with cervical cancer undergoing concurrent chemoradiation therapy (CCRT). Molecular hydrogen, as a novel antioxidant and anti-inflammatory agent, may alleviate treatment-related toxicity. This study aimed to evaluate the efficacy of inhaled hydrogen in preventing ARE and modulating systemic inflammation. METHODS: Eligible patients with cervical cancer undergoing CCRT were prospectively enrolled and randomized into an experimental group (n = 28) or a control group (n = 30). The experimental group received inhalation therapy with a hydrogen-oxygen gas mixture (66.6% hydrogen, 33.3% oxygen; 3 L/min, 2 h/d) on each radiation therapy day. Inflammatory biomarkers-including C-reactive protein, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and interleukin 6-as well as hemogram parameters, fecal occult blood, Late Effects Normal Tissue Task Force-Subjective, Objective, Management, and Analytic scores; Patient-Generated Subjective Global Assessment scores; and Radiation Therapy Oncology Group enteritis grades were monitored during treatment and Response Evaluation Criteria in Solid Tumors scores. RESULTS: Baseline characteristics (age, tumor stage, pathology, and surgical history) were balanced between groups (P > .05). Compared with the control group, the experimental group showed significantly lower levels of C-reactive protein, neutrophil-to-lymphocyte ratio, interleukin 6, and fecal occult blood positivity rates (P < .05). Clinical assessments also indicated lower Late Effects Normal Tissue Task Force-Subjective, Objective, Management, and Analytic and Patient-Generated Subjective Global Assessment scores and milder Radiation Therapy Oncology Group enteritis grading in the hydrogen group (P < .05). Importantly, no significant difference in tumor response was observed between groups based on the Response Evaluation Criteria in Solid Tumors, suggesting that hydrogen therapy did not interfere with the antitumor efficacy of CCRT. No adverse events related to hydrogen inhalation were reported. CONCLUSION: Hydrogen inhalation is a safe and effective adjunctive therapy that significantly alleviates inflammation and mitigates clinical symptoms of ARE in patients with cervical cancer who are undergoing CCRT, without compromising antitumor treatment outcomes.
引用
- Liu B, Bao Y, Ma J, et al. Clinical Efficacy of Hydrogen Therapy on Acute Radiation Enteritis and Inflammatory Response in Patients with Cervical Cancer Undergoing Concurrent Chemoradiation Therapy. Adv Radiat Oncol. 2025. PMID: 41020280. doi:10.1016/j.adro.2025.101879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。